文献速递心境障碍会诊联络精神医学

抗抑郁药使用与COVID-19住院患者插管或死亡风险降低相关:一项观察性研究

Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study.
PubMed 文献 · Mol Psychiatry · 2021-02-04

该多中心回顾性队列研究纳入7230例COVID-19住院成人,其中345例(4.8%)在入院48小时内接受抗抑郁药。经多变量Cox模型及逆概率加权调整后,抗抑郁药使用与插管或死亡复合终点风险显著降低相关(HR 0.56,95%CI 0.43-0.73,p<0.001),敏感性分析结果一致。

要点

  • COVID-19住院患者入院48小时内使用抗抑郁药与插管或死亡风险降低显著相关(HR 0.56)。
  • 该关联在SSRI与非SSRI抗抑郁药及氟西汀、帕罗西汀、艾司西酞普兰、文拉法辛、米氮平均显著(p<0.05)。
  • 结果为观察性研究,需双盲随机对照试验验证抗抑郁药对COVID-19的疗效。

核心结论

  • 抗抑郁药使用可能与COVID-19住院患者插管或死亡风险降低相关。
  • 需开展双盲随机对照临床试验验证抗抑郁药对COVID-19的作用。

研究设计与样本

  • 多中心回顾性观察性队列研究,在AP-HP大巴黎大学医院开展。
  • 纳入7230例COVID-19住院成人,345例(4.8%)在入院48小时内接受抗抑郁药。
  • 主要分析为多变量Cox模型结合逆概率加权,调整患者特征、疾病严重度临床与生物学标志物及其他精神药物。

主要发现

  • 抗抑郁药使用与插管或死亡复合终点风险降低显著相关(HR 0.56;95%CI 0.43-0.73;p<0.001)。
  • 该关联在多项敏感性分析中保持显著。
  • 探索性分析显示SSRI与非SSRI抗抑郁药及氟西汀、帕罗西汀、艾司西酞普兰、文拉法辛、米氮平均与终点显著相关(均p<0.05)。

关键数值与推荐

  • 主要终点为插管或死亡的复合终点。
  • 主要分析采用多变量Cox模型联合逆概率加权,调整患者特征、疾病严重度标志物及其他精神药物。

临床怎么用

  • 临床可关注正在使用抗抑郁药的COVID-19住院患者,但不应据此改变抗抑郁药处方以适应COVID-19治疗。
  • 抗抑郁药对COVID-19的潜在获益需等待随机对照试验证实。

局限性

  • 为观察性回顾性队列研究,存在残余混杂可能。
  • 抗抑郁药暴露定义为入院48小时内使用,暴露窗口有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A prior meta-analysis showed that antidepressant use in major depressive disorder was associated with reduced plasma levels of several pro-inflammatory mediators, which have been associated with severe COVID-19. Recent studies also suggest that several antidepressants may inhibit acid sphingomyelinase activity, which may prevent the infection of epithelial cells with SARS-CoV-2, and that the SSRI fluoxetine may exert in-vitro antiviral effects on SARS-CoV-2. We examined the potential usefulness of antidepressant use in patients hospitalized for COVID-19 in an observational multicenter retrospective cohort study conducted at AP-HP Greater Paris University hospitals. Of 7230 adults hospitalized for COVID-19, 345 patients (4.8%) received an antidepressant within 48 h of hospital admission. The primary endpoint was a composite of intubation or death. We compared this endpoint between patients who received antidepressants and those who did not in time-to-event analyses adjusted for patient characteristics, clinical and biological markers of disease severity, and other psychotropic medications. The primary analysis was a multivariable Cox model with inverse probability weighting. This analysis showed a significant association between antidepressant use and reduced risk of intubation or death (HR, 0.56; 95% CI, 0.43-0.73, p < 0.001). This association remained significant in multiple sensitivity analyses. Exploratory analyses suggest that this association was also significant for SSRI and non-SSRI antidepressants, and for fluoxetine, paroxetine, escitalopram, venlafaxine, and mirtazapine (all p < 0.05). These results suggest that antidepressant use could be associated with lower risk of death or intubation in patients hospitalized for COVID-19. Double-blind controlled randomized clinical trials of antidepressant medications for COVID-19 are needed.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hoertel N, Sánchez-Rico M, Vernet R, et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021. PMID: 33536545. doi:10.1038/s41380-021-01021-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。